ICCM IceCure Medical | $0.84
+2.4% | 8/13/2025 | - | Reiterated Rating | Buy -> Buy | | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 8/13/2025 |
YMAB Y-mAbs Therapeutics | $8.51
| 8/5/2025 | - | Downgrade | Strong-Buy -> Hold | | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 8/5/2025 |
RADX Radiopharm Theranostics | $5.38
+3.1% | 7/21/2025 | Kemp Dolliver | Initiated Coverage | Buy | $18.00 | View details for Brookline Capital Management rating of Radiopharm Theranostics (NASDAQ:RADX) on 7/21/2025 |
LSTA Lisata Therapeutics | $2.69
+2.7% | 7/15/2025 | Kemp Dolliver | Boost Price Target | Buy -> Buy | $20.00 -> $32.00 | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 7/15/2025 |
CADL Candel Therapeutics | $6.40
+0.8% | 7/9/2025 | K. Dolliver | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Candel Therapeutics (NASDAQ:CADL) on 7/9/2025 |
HURA TuHURA Biosciences | $2.84
-12.6% | 6/23/2025 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of TuHURA Biosciences (NASDAQ:HURA) on 6/23/2025 |
CRVO CervoMed | $9.64
+2.6% | 3/11/2025 | T. Bussian | Upgrade | Hold -> Strong-Buy | | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 3/11/2025 |
CATX Perspective Therapeutics | $3.81
-4.3% | 3/10/2025 | K. Dolliver | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Perspective Therapeutics (NYSE:CATX) on 3/10/2025 |
IMAB I-Mab | $4.24
+10.1% | 2/27/2025 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 2/27/2025 |
MRKR Marker Therapeutics | $1.29
+0.8% | 2/10/2025 | L. Cann | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Marker Therapeutics (NASDAQ:MRKR) on 2/10/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
CGTX Cognition Therapeutics | $1.22
+10.9% | 1/27/2025 | T. Bussian | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Cognition Therapeutics (NASDAQ:CGTX) on 1/27/2025 |
MDCX Medicus Pharma | $2.10
-6.3% | 12/23/2024 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Medicus Pharma (NASDAQ:MDCX) on 12/23/2024 |
EXEL Exelixis | $38.49
+1.4% | 12/23/2024 | L. Cann | Initiated Coverage | Buy | | View details for Brookline Capital Management rating of Exelixis (NASDAQ:EXEL) on 12/23/2024 |
QNCX Quince Therapeutics | $1.72
-6.0% | 12/18/2024 | K. Raja | Initiated Coverage | Buy | $9.00 | View details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024 |
CRVO CervoMed | $9.64
+2.6% | 12/10/2024 | T. Bussian | Downgrade | Strong-Buy -> Hold | | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024 |
YMAB Y-mAbs Therapeutics | $8.51
| 12/4/2024 | K. Dolliver | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024 |
YMAB Y-mAbs Therapeutics | $8.51
| 12/5/2024 | - | Initiated Coverage | Buy | $17.00 | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024 |
HYPD Hyperion DeFi | $7.04
-2.6% | 11/15/2024 | K. Dolliver | Reiterated Rating | Buy -> Hold | | View details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 11/15/2024 |
COCH Envoy Medical | $1.48
+0.7% | 10/14/2024 | T. Bussian | Initiated Coverage | Buy | $9.00 | View details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024 |
VRCA Verrica Pharmaceuticals | $6.59
-3.4% | 10/2/2024 | K. Dolliver | Reiterated Rating | Buy -> Hold | | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024 |
OSTX OS Therapies | $1.88
+5.6% | 8/22/2024 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024 |
MEIP MEI Pharma | $5.14
+7.3% | 7/22/2024 | L. Cann | Downgrade | Strong-Buy -> Hold | | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 7/22/2024 |
IBIO iBio | $0.73
+27.2% | 7/22/2024 | K. Dolliver | Initiated Coverage | Buy | $3.60 | View details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024 |
UNCY Unicycive Therapeutics | $4.41
+3.8% | 7/9/2024 | K. Raja | Upgrade | Strong-Buy | | View details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024 |
CRVO CervoMed | $9.64
+2.6% | 7/8/2024 | T. Bussian | Initiated Coverage | Buy | $63.00 | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024 |
SABS SAB Biotherapeutics | $2.15
-0.5% | 6/7/2024 | - | Initiated Coverage | Buy | $8.00 | View details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024 |
FBRX Forte Biosciences | $10.57
-1.8% | 5/30/2024 | - | Initiated Coverage | Buy | $4.00 | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024 |
DARE Dare Bioscience | $2.11
+3.9% | 5/15/2024 | K. Dolliver | Upgrade | Hold -> Buy | $36.00 | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 5/15/2024 |
DARE Dare Bioscience | $2.11
+3.9% | 4/17/2024 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $0.83
-2.7% | 4/5/2024 | T. Bussian | Reiterated Rating | Buy | $10.00 | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
ATBPF Antibe Therapeutics | $0.22
| 3/4/2024 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $2.70
-2.6% | 2/28/2024 | T. Bussian | Downgrade | Buy -> Hold | $9.00 | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
OTLK Oncobiologics | $2.13
+1.9% | 1/25/2024 | K. Dolliver | Upgrade | Hold -> Buy | $31.40 | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 1/25/2024 |
CYCC Cyclacel Pharmaceuticals | $8.90
-4.1% | 12/19/2023 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 12/19/2023 |
LNTH Lantheus | $53.79
-0.2% | 11/30/2023 | - | Initiated Coverage | Buy | $100.00 | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $2.70
-2.6% | 11/10/2023 | T. Bussian | Reiterated Rating | Buy | $35.00 | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $3.20
+0.3% | 10/30/2023 | K. Dolliver | Upgrade | Hold -> Buy | | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
HYPD Hyperion DeFi | $7.04
-2.6% | 10/17/2023 | - | Initiated Coverage | Buy | $640.00 | View details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 10/17/2023 |
EDSA Edesa Biotech | $2.19
+0.9% | 10/12/2023 | - | Reiterated Rating | Buy -> Buy | $57.00 | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
OTLK Oncobiologics | $2.13
+1.9% | 8/30/2023 | K. Dolliver | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 8/30/2023 |
Special gold investment soars 2,300% ... 5,090% ... 9,850% (Ad) In my 54 years as an investor, I’ve seen my share of gold bull markets.
But nothing comes close to the rally right now.
Over the past few weeks alone, the yellow metal surged as high as $3,500 — the highest level on record.
So far this bull run playing out exactly as me and my analysts have predicted. Here’s exactly how we see this gold bull market play out. |
ATBPF Antibe Therapeutics | $0.22
| 8/14/2023 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
DARE Dare Bioscience | $2.11
+3.9% | 2/14/2023 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 2/14/2023 |
ECOR electroCore | $5.14
+14.7% | 1/12/2023 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
IMNN Imunon | $6.70
-2.0% | 11/14/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022 |
VXRT Vaxart | $0.38
+1.2% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022 |
OTLK Oncobiologics | $2.13
+1.9% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $33.51
-6.7% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
LSTA Lisata Therapeutics | $2.69
+2.7% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
IMNN Imunon | $6.70
-2.0% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022 |
EDSA Edesa Biotech | $2.19
+0.9% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
CYCC Cyclacel Pharmaceuticals | $8.90
-4.1% | 10/3/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 10/3/2022 |
ARCT Arcturus Therapeutics | $19.21
+29.0% | 8/10/2022 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22
| 6/30/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $3.41
+7.6% | 5/18/2022 | Kumaraguru Raja | Boost Price Target | Buy -> Buy | $290.00 -> $310.00 | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $6.59
-3.4% | 3/10/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $11.00
+1.3% | 3/7/2022 | L. Cann | Upgrade | Hold -> Buy | $91.00 | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $57.87
+2.2% | 2/14/2022 | Leah Rush | Reiterated Rating | Buy | $143.00 | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $11.00
+1.3% | 2/14/2022 | Leah Rush | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $1.95
+8.9% | 2/14/2022 | L. Cann | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
ICCM IceCure Medical | $0.84
+2.4% | 2/1/2022 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
DARE Dare Bioscience | $2.11
+3.9% | 1/19/2022 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 1/19/2022 |
KYMR Kymera Therapeutics | $40.73
+2.2% | 10/13/2021 | Leah Rush Cann | Reiterated Rating | Buy | $80.00 | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $10.57
-1.8% | 9/3/2021 | K. Raja | Reiterated Rating | Hold | | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $3.41
+7.6% | 8/27/2021 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $0.85
-1.7% | 8/24/2021 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $2.33
+4.0% | 6/25/2021 | Leah Rush Cann | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATBPF Antibe Therapeutics | $0.22
| 6/3/2021 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $33.51
-6.7% | 5/25/2021 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $3.12
-1.9% | 5/7/2021 | K. Dolliver | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
MRNA Moderna | $26.89
+4.8% | 2/26/2021 | - | Boost Price Target | Buy | $180.00 -> $205.00 | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
XFOR X4 Pharmaceuticals | $2.93
+13.6% | 12/17/2020 | L. Cann | Initiated Coverage | Buy | $630.00 | View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020 |
VERU Veru | $3.41
+7.6% | 12/14/2020 | K. Raja | Boost Price Target | | $130.00 -> $170.00 | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
ECOR electroCore | $5.14
+14.7% | 10/23/2020 | S. Yanchus | Initiated Coverage | Buy | $75.00 | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
MEIP MEI Pharma | $5.14
+7.3% | 10/12/2020 | L. Cann | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020 |
FBRX Forte Biosciences | $10.57
-1.8% | 8/28/2020 | K. Raja | Initiated Coverage | Buy | $90.00 | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
KURA Kura Oncology | $6.49
+4.7% | 8/16/2020 | L. Cann | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $3.41
+7.6% | 8/14/2020 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $19.21
+29.0% | 8/11/2020 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
MRNA Moderna | $26.89
+4.8% | 7/13/2020 | L. Cann | Reiterated Rating | Buy | $95.00 | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.81
-1.6% | 6/3/2020 | - | Initiated Coverage | Buy | $3.50 | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
CYCC Cyclacel Pharmaceuticals | $8.90
-4.1% | 5/19/2020 | K. Raja | Initiated Coverage | Buy | $79,200.00 | View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 5/19/2020 |
OTLK Oncobiologics | $2.13
+1.9% | 5/5/2020 | K. Raja | Initiated Coverage | Buy | | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 5/5/2020 |
DARE Dare Bioscience | $2.11
+3.9% | 4/28/2020 | S. Yanchus | Initiated Coverage | Buy | $90.00 | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $2.19
+0.9% | 3/30/2020 | K. Raja | Initiated Coverage | Buy | $70.00 | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $11.92
+13.1% | 3/11/2020 | S. Yanchus | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $2.50
+1.6% | 3/13/2020 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $11.92
+13.1% | 3/12/2020 | - | Initiated Coverage | Buy | $15.00 | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $33.51
-6.7% | 2/19/2020 | K. Raja | Initiated Coverage | Buy | $210.00 | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $3.12
-1.9% | 2/4/2020 | S. Yanchus | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
MDNA Medicenna Therapeutics | C$1.00
-5.7% | 11/19/2019 | - | Reiterated Rating | Buy | C$4.00 | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
New law could create $3.7 trillion tsunami. (Ad) During a meeting in Washington D.C., Jeff Brown discovered a bold initiative.
He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard.
The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.”
Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. You can watch it right here. |
SCYX SCYNEXIS | $0.85
-1.7% | 8/19/2019 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT Vaxart | $0.38
+1.2% | 8/15/2019 | K. Raja | Initiated Coverage | Buy | $6.00 | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019 |
VERU Veru | $3.41
+7.6% | 7/29/2019 | K. Raja | Initiated Coverage | Buy | $120.00 | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
ARCT Arcturus Therapeutics | $19.21
+29.0% | 7/24/2019 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
SCYX SCYNEXIS | $0.85
-1.7% | 1/4/2019 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
ARCT Arcturus Therapeutics | $19.21
+29.0% | 9/27/2018 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $61.57
+3.0% | 7/27/2018 | K. Raja | Downgrade | Buy -> Hold | | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $61.57
+3.0% | 5/1/2018 | K. Raja | Reiterated Rating | Buy | | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |
MarketBeat All Access